Jobs
-
Horizon Pharma has agreed to sell Raptor Pharmaceuticals, which owns the rights to Quinsair levofloxacin inhalation solution in Europe, the Middle East and Africa, to Chiesi Farmaceutici for $70 million and potential sales-based milestone payments,… Read more . . .
-
Generic device company Merxin has announced the launch of its MRX003 dry powder inhaler, an off-the-shelf capsule based DPI intended for generic tiotropium 505j submissions. According to an announcement by Merxin’s sister company Aedestra, the… Read more . . .
-
Windtree Therapeutics has received $900,000 from a Small Business Innovation Research Grant (SBIR) grant for Phase 2b trial of Aerosurf aerosolized KL4 surfactant in premature infants with respiratory distress syndrome (RDS) who are receiving nasal… Read more . . .
-
Vectura has announced that it is presenting positive results from a Phase I clinical study of VR942, an inhaled anti-IL-13 monoclonal fragment antibody, at the American Thoracic Society 2017 International Conference. Vectura is partnered with… Read more . . .
-
Chiesi Group has announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion regarding the company’s MAA for Trimbow beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide MDI. Chiesi has applied to… Read more . . .
-
Submit abstracts by 28 July 2017 at https://aerosol-soc.com/abstract-submission/ Themes for DDL 2017 are Inhaled Therapy in Special Populations, Emerging Therapeutics and Novel Respiratory Medicines, Inhalation Devices and Aerosol Science, and Modelling and Simulations in Inhalation… Read more . . .
-
Acorda Therapeutics will present new data from a Phase 3 trial of its CVT-301 inhaled L-dopa, which it is now calling Inbrija, at the International Congress of Parkinson’s Disease and Movement Disorders (MDS). The company… Read more . . .
-
Lactose manufacturer Meggle has announced the launch of InhaLac 500 micronized lactose for dry powder inhalation formulations, saying “Combined with high quality and safety, this material meets the most demanding individual dry powder inhalation formulation… Read more . . .
-
Aptar Pharma has announced that its partner Takeda Pharmaceuticals has received approval from the EMA to market a multidose version of its Instanyl fentanyl nasal spray that includes Aptar’s e-Lockout integrated electronic lockout device. According… Read more . . .
-
Arikayce inhaled amikacin deveoper Insmed Incorporated has announced the appointments of Paolo Tombesi as Chief Financial Officer, Paul Streck as Chief Medical Officer, and Eugene Sullivan as Chief Product Strategy Officer. Tombesi was most recently… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA